Antidepressant Mechanisms of Transcranial Magnetic Stimulation
Primary Purpose
Depression
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Repetitive transcranial magnetic stimulation
Sponsored by

About this trial
This is an interventional treatment trial for Depression focused on measuring Magnetic stimulation of the brain, Antidepressant mechanisms
Eligibility Criteria
Inclusion Criteria:
- A history of major depressive disorder by the Structured Clinical Interview for DSM-IV (SCID)
- Failure to respond to at least two previous antidepressant trials at adequate doses for 8 weeks (for current or prior major depressive episodes)
- A minimum 17-item Hamilton depression rating scale of 17 on both the screening day and the treatment day #1
- Age 18-70
- Participants may be taking antidepressants, antipsychotics, or low-dose mood stabilizers during the study
- Participants may be in psychotherapy during the study
Exclusion Criteria:
- Participants with metal implants (Will use the NY Presbyterian Hospital MRI Checklist)
- Prior exposure to TMS
- Pregnant women
- Lactating women
- Bipolar disorder (on the Structured Clinical Interview for DSM-IV (SCID)
- Current depressive episode longer than 3 years
- Active suicidal ideation with plan or intent
- Borderline personality disorder (on the Structured Clinical Interview for DSM-IV (SCID)
- Substance abuse or dependence with the past 3 years
- Current urine drug screen positive for any drugs of abuse
- Current symptoms of psychosis
- History of seizure disorder
- History of closed head injury with loss of consciousness
- History of brain surgery
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Active rTMS
Arm Description
Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
Outcomes
Primary Outcome Measures
Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item)
The Hamilton Depression Rating Scale is 24 items with total scores ranging from 0-76. Higher scores indicate greater severity of depression. (0-7 = None; 8-13 = Mild; 14-18 = Moderate; 19-23 = Severe; 23 and higher = very severe). Total scores are reported with no subscales.
Secondary Outcome Measures
Depression Severity Measured by the Public Health Questionnaire-9
Self-rated scale of symptoms of depression. Nine items with a maximum score of 27. Higher score means more severe depression (0-4 = None; 5-9 = Mild; 10-14 = Moderate; 15-19 = Severe; 20 and higher = Very Severe).
Full Information
NCT ID
NCT02466230
First Posted
May 28, 2015
Last Updated
August 9, 2018
Sponsor
Weill Medical College of Cornell University
Collaborators
National Alliance for Research on Schizophrenia and Depression, Neuronetics
1. Study Identification
Unique Protocol Identification Number
NCT02466230
Brief Title
Antidepressant Mechanisms of Transcranial Magnetic Stimulation
Official Title
Predictive and Response Biomarkers of Effective Treatment With Transcranial Magnetic Stimulation for Major Depressive Disorder
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
October 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weill Medical College of Cornell University
Collaborators
National Alliance for Research on Schizophrenia and Depression, Neuronetics
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study utilizes resting state fMRI, arterial spin labelling imaging, diffusion tensor imaging, structural MR-imaging, and MR-spectroscopy of GABA and Glutamate to probe the antidepressant mechanisms of repetitive transcranial magnetic stimulation (rTMS). The above imaging modalities will be acquired before and after an open-label 5 week course of rTMS for depression in currently depressed individuals with treatment resistant depression. Changes in functional, structural, and neurochemical markers will be investigated in rTMS responders and nonresponders to elucidate mechanisms of plasticity that correlate with treatment response. Additionally, functional, structural, and neurochemical signatures at baseline that correlate with subsequent treatment response will be investigated.
Detailed Description
Repetitive Transcranial Magnetic Stimulation (rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) alleviates mood in major depression. This treatment received FDA approval in 2009 and is now in routine clinical use for the treatment of major depression. A recently published sham-controlled study showed a response rate of 14% in real rTMS compared to 5% in sham rTMS. The response, defined by a greater than 50% reduction in the Hamilton Depression Rating Scale from pre-treatment to post-treatment, was also found to be 14% in one recent meta-analysis. The inclusion criteria in these studies admitted a broad spectrum of participants, ranging from subjects having a first major depressive episode, to those having failed multiple medication trials, suggesting that a subgroup with a more robust response may be masked by an unresponsive group. Abnormal function of the left frontal lobe accompanies major depression and this may be normalized by rTMS Cerebral blood flow measured with SPECT imaging was reduced in the left DLPFC of depressed subjects and was increased during and after a course of rTMS over the left DLPFC. Decreased blood flow was found in a broader region of frontal and paralimbic regions in depressed individuals and treatment success was associated with decreased blood flow in the inferior frontal lobes both pre- and post- treatment. Greater post-treatment vs. pre-treatment BOLD activation of left frontal regions was demonstrated using fMRI in a planning task that engages the frontal lobes. Left prefrontal myo-inositol is reduced in depressed subjects and this is normalized by rTMS. The above functional abnormalities view the frontal lobe in isolation. However, recent work has demonstrated a network-based structural marker of risk for familial depression consisting of decreased cortical and white mater volume. Resting state fMRI (rs-fMRI) tests cross-regional temporal coherence in low frequency oscillations in brain responses (~0.1 Hz) that are believed to represent spontaneous neural activity. Correlated spontaneous fluctuations are understood to reflect functional connections between brain regions that arise through a history of co-activation across one's lifetime. Previous work has shown that depressed patients exhibit altered functional connectivity patterns as gauged by rs-fMRI, and some studies suggest that these differences may be mitigated by treatment with antidepressant medications. However, whether and how TMS may affect functional connectivity is unknown. I propose to acquire the several described MRI types both before and after rTMS treatment in a search for predictive markers of rTMS treatment success as well as markers of treatment-induced change. Arterial spin labeling will be acquired to measure the blood flow distribution throughout the brain, both to confirm the SPECT results already reported and to test for additional regions of change. Resting state fMRI will be collected and DTI will be used to explore the structural basis of functional network changes. Structural MRI will be collected to measure cortical thickness and white matter volumes that may be predictive of rTMS response. Magnetic resonance spectroscopy will be collected to confirm the previously reported finding of rTMS-induced myo-inositol changes, as well as to consider the Glutamate/Glutamine and GABA spectra, given the importance of these neurotransmitters in theories of depression.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
Keywords
Magnetic stimulation of the brain, Antidepressant mechanisms
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active rTMS
Arm Type
Experimental
Arm Description
Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
Intervention Type
Device
Intervention Name(s)
Repetitive transcranial magnetic stimulation
Intervention Description
Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
Primary Outcome Measure Information:
Title
Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item)
Description
The Hamilton Depression Rating Scale is 24 items with total scores ranging from 0-76. Higher scores indicate greater severity of depression. (0-7 = None; 8-13 = Mild; 14-18 = Moderate; 19-23 = Severe; 23 and higher = very severe). Total scores are reported with no subscales.
Time Frame
Change in score on Hamilton Depression Rating Scale from baseline to immediately after the final rTMS treatment (5 weeks)
Secondary Outcome Measure Information:
Title
Depression Severity Measured by the Public Health Questionnaire-9
Description
Self-rated scale of symptoms of depression. Nine items with a maximum score of 27. Higher score means more severe depression (0-4 = None; 5-9 = Mild; 10-14 = Moderate; 15-19 = Severe; 20 and higher = Very Severe).
Time Frame
Change in score in Public Health Questionnaire-9 from baseline to immediately after the final rTMS treatment (5 weeks)
Other Pre-specified Outcome Measures:
Title
Gamma-amino-butyric Acid Level Measured by Magnetic Resonance Spectroscopy
Description
Percent change in medial prefrontal gamma-amino-butyric acid level
Time Frame
Baseline to immediately after the final rTMS treatment (5 weeks)
Title
Glutamate Level Measured by Magnetic Resonance Spectroscopy
Description
Percent change in medial prefrontal glutamate level
Time Frame
Baseline to immediately after the final rTMS treatment (5 weeks)
Title
Cortical Thickness Measured by T1 Magnetic Resonance Imaging
Description
Percent change in medial prefrontal average cortical thickness
Time Frame
Baseline to immediately after the final rTMS treatment (5 weeks)
Title
Fractional Anisotropy Measured by Diffusion Tensor Imaging
Description
Percent change in medial prefrontal average fractional anisotropy
Time Frame
Baseline to immediately after the final rTMS treatment (5 weeks)
Title
Functional Connectivity Measured by Functional Magnetic Resonance Imaging
Description
Percent change in medial prefrontal average functional connectivity
Time Frame
Baseline to immediately after the final rTMS treatment (5 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
A history of major depressive disorder by the Structured Clinical Interview for DSM-IV (SCID)
Failure to respond to at least two previous antidepressant trials at adequate doses for 8 weeks (for current or prior major depressive episodes)
A minimum 17-item Hamilton depression rating scale of 17 on both the screening day and the treatment day #1
Age 18-70
Participants may be taking antidepressants, antipsychotics, or low-dose mood stabilizers during the study
Participants may be in psychotherapy during the study
Exclusion Criteria:
Participants with metal implants (Will use the NY Presbyterian Hospital MRI Checklist)
Prior exposure to TMS
Pregnant women
Lactating women
Bipolar disorder (on the Structured Clinical Interview for DSM-IV (SCID)
Current depressive episode longer than 3 years
Active suicidal ideation with plan or intent
Borderline personality disorder (on the Structured Clinical Interview for DSM-IV (SCID)
Substance abuse or dependence with the past 3 years
Current urine drug screen positive for any drugs of abuse
Current symptoms of psychosis
History of seizure disorder
History of closed head injury with loss of consciousness
History of brain surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc J Dubin, MD, PhD
Organizational Affiliation
Weill Medical College of Cornell University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Antidepressant Mechanisms of Transcranial Magnetic Stimulation
We'll reach out to this number within 24 hrs